IL283990A - Modified oxopyridine derivatives - Google Patents
Modified oxopyridine derivativesInfo
- Publication number
- IL283990A IL283990A IL283990A IL28399021A IL283990A IL 283990 A IL283990 A IL 283990A IL 283990 A IL283990 A IL 283990A IL 28399021 A IL28399021 A IL 28399021A IL 283990 A IL283990 A IL 283990A
- Authority
- IL
- Israel
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- oxopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 | ||
| PCT/EP2019/085983 WO2020127504A1 (fr) | 2018-12-21 | 2019-12-18 | Dérivés d'oxopyridine substitués |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283990A true IL283990A (en) | 2021-07-29 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283990A IL283990A (en) | 2018-12-21 | 2021-06-14 | Modified oxopyridine derivatives |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (fr) |
| JP (1) | JP2022514303A (fr) |
| KR (1) | KR20210106504A (fr) |
| CN (1) | CN113474348A (fr) |
| AR (1) | AR117435A1 (fr) |
| AU (1) | AU2019407909B2 (fr) |
| BR (1) | BR112021009435A2 (fr) |
| CA (1) | CA3124220A1 (fr) |
| CL (1) | CL2021001613A1 (fr) |
| CO (1) | CO2021007908A2 (fr) |
| CR (1) | CR20210342A (fr) |
| DO (1) | DOP2021000128A (fr) |
| EA (1) | EA202191764A1 (fr) |
| EC (1) | ECSP21043895A (fr) |
| IL (1) | IL283990A (fr) |
| JO (1) | JOP20210161A1 (fr) |
| MA (1) | MA54521A (fr) |
| MX (1) | MX2021007508A (fr) |
| PE (1) | PE20211790A1 (fr) |
| SG (1) | SG11202104384PA (fr) |
| TW (1) | TW202039510A (fr) |
| WO (1) | WO2020127504A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020018562A2 (pt) * | 2018-03-15 | 2020-12-29 | Bayer Aktiengesellschaft | Processo preparativo |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| MX2023010629A (es) | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida. |
| JP2024508971A (ja) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－５ ジベンゼナヘプタファン－７４－カルボキサミドの結晶形態 |
| WO2022189280A1 (fr) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| JP6410819B2 (ja) | 2013-07-23 | 2018-10-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用 |
| WO2015063093A1 (fr) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substituée |
| EP3197880B1 (fr) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués à effet anti-inflammatoire et anti-thrombotique |
| US10138236B2 (en) * | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| EP3197873B1 (fr) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| EP3197889B1 (fr) | 2014-09-24 | 2018-08-01 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| US10077265B2 (en) * | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| EP3197872B1 (fr) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | (2h)-2-oxopyridines en tant qu'inhibiteurs du facteur xia pour le traitement de maladies thrombotiques |
| EP3271332A1 (fr) * | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3344618A1 (fr) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
-
2019
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 CA CA3124220A patent/CA3124220A1/fr active Pending
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/fr unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/fr active Pending
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3898633A1 (fr) | 2021-10-27 |
| DOP2021000128A (es) | 2021-09-30 |
| TW202039510A (zh) | 2020-11-01 |
| CN113474348A (zh) | 2021-10-01 |
| BR112021009435A2 (pt) | 2021-08-17 |
| WO2020127504A1 (fr) | 2020-06-25 |
| SG11202104384PA (en) | 2021-05-28 |
| AU2019407909B2 (en) | 2023-05-25 |
| CO2021007908A2 (es) | 2021-07-19 |
| KR20210106504A (ko) | 2021-08-30 |
| CR20210342A (es) | 2021-08-09 |
| ECSP21043895A (es) | 2021-07-30 |
| JP2022514303A (ja) | 2022-02-10 |
| PE20211790A1 (es) | 2021-09-09 |
| EA202191764A1 (ru) | 2021-10-22 |
| JOP20210161A1 (ar) | 2023-01-30 |
| CL2021001613A1 (es) | 2021-12-03 |
| CA3124220A1 (fr) | 2020-06-25 |
| AR117435A1 (es) | 2021-08-04 |
| MX2021007508A (es) | 2021-08-05 |
| MA54521A (fr) | 2022-03-30 |
| AU2019407909A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE060181T2 (hu) | Szubsztituált alkoxipiridinil-indolszulfonamidok | |
| IL283197A (en) | Biocidal 2-acylamino-thiazole-4-carboxamide derivatives | |
| IL271607B1 (en) | New azaquinoline histories | |
| CA185382S (en) | Casque | |
| ZA202204675B (en) | New methylquinazolinone derivatives | |
| IL283990A (en) | Modified oxopyridine derivatives | |
| IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
| IL289197A (en) | History of 2-hydroxycycloalkane-1-carbamoyl | |
| SI3796975T1 (sl) | Derivati sulfonilaminobenzamida | |
| CA184991S (en) | Uroflowmeter | |
| IL279938A (en) | History of spirochroman | |
| CA184994S (en) | Uroflowmeter | |
| IL290815A (en) | History of alpha-d-galactopyranoside | |
| HUE062256T2 (hu) | Dihidrokromén-származékok | |
| SG11202006837XA (en) | Dihydroindolizinone derivative | |
| GB201806948D0 (en) | Derivatives | |
| GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| AU201817248S (en) | MC-Roller | |
| AU201817247S (en) | MC-Roller | |
| AU201817245S (en) | MC-Roller | |
| PT3319956T (pt) | Derivados de oxopiridina substituída |